ASX Stocks Estimated To Be Trading Below Fair Value In July 2025

Simply Wall St

As the Reserve Bank of Australia holds interest rates steady amidst economic uncertainty, the Australian market has seen mixed performances across sectors, with IT leading gains and materials paring losses. In this environment, identifying stocks that are trading below their fair value can provide investors with opportunities to capitalize on potential market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In Australia

NameCurrent PriceFair Value (Est)Discount (Est)
Praemium (ASX:PPS)A$0.68A$1.3650%
PointsBet Holdings (ASX:PBH)A$1.185A$2.1043.5%
Pantoro Gold (ASX:PNR)A$3.26A$5.5240.9%
Nuix (ASX:NXL)A$2.04A$3.3238.6%
Integral Diagnostics (ASX:IDX)A$2.54A$4.5744.5%
Infomedia (ASX:IFM)A$1.20A$2.0742%
Fenix Resources (ASX:FEX)A$0.28A$0.5144.7%
Collins Foods (ASX:CKF)A$8.95A$15.7443.1%
Charter Hall Group (ASX:CHC)A$19.21A$35.4345.8%
Advanced Braking Technology (ASX:ABV)A$0.084A$0.1648.9%

Click here to see the full list of 35 stocks from our Undervalued ASX Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Capricorn Metals (ASX:CMM)

Overview: Capricorn Metals Ltd is involved in the evaluation, exploration, development, and production of gold properties in Australia with a market cap of A$4.16 billion.

Operations: The company's revenue primarily comes from its Karlawinda gold operations, generating A$379.47 million.

Estimated Discount To Fair Value: 33.2%

Capricorn Metals is trading at A$9.65, significantly below its estimated fair value of A$14.45, suggesting it may be undervalued based on cash flows. Recent repayment of a $50 million debt strengthens its financial position, supporting future growth projects like Karlawinda and Mt Gibson. With earnings forecasted to grow 25% annually and revenue expected to increase by 22% per year, Capricorn's strong cash generation positions it well for continued expansion despite recent executive changes.

ASX:CMM Discounted Cash Flow as at Jul 2025

Integral Diagnostics (ASX:IDX)

Overview: Integral Diagnostics Limited is a healthcare services company that provides diagnostic imaging services to medical professionals and patients in Australia and New Zealand, with a market cap of A$945.43 million.

Operations: The company generates revenue from the operation of diagnostic imaging facilities, amounting to A$491.32 million.

Estimated Discount To Fair Value: 44.5%

Integral Diagnostics is trading at A$2.54, well below its estimated fair value of A$4.57, indicating potential undervaluation based on cash flows. Despite recent shareholder dilution, earnings are projected to grow significantly at 32.89% annually over the next three years, outpacing the Australian market's growth rate of 10.9%. However, interest payments remain a concern as they are not fully covered by earnings. Revenue growth is expected to exceed the market average but remains moderate overall.

ASX:IDX Discounted Cash Flow as at Jul 2025

Meeka Metals (ASX:MEK)

Overview: Meeka Metals Limited is involved in the exploration and development of gold properties in Western Australia, with a market cap of A$422.78 million.

Operations: Meeka Metals Limited does not currently report revenue from its exploration and development activities in Western Australia.

Estimated Discount To Fair Value: 28.1%

Meeka Metals, priced at A$0.15, trades significantly below its estimated fair value of A$0.20, reflecting potential undervaluation based on cash flows. Despite generating less than US$1m in revenue (A$329K), the company anticipates robust revenue growth of 56.1% annually, surpassing market averages. Forecasts predict profitability within three years and a high future return on equity of 45.6%. However, recent shareholder dilution through a A$60 million equity offering is noteworthy.

ASX:MEK Discounted Cash Flow as at Jul 2025

Next Steps

Interested In Other Possibilities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Integral Diagnostics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com